CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
'We entered 2025 with a strong momentum and robust balance sheet, driven by progress across our oncology and infectious disease programs, as well as successful execution of our strategic realignment,' said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. 'With the FDA's clearance of the IND for our lung cancer program and our glioblastoma study fully enrolled, we are steadily advancing an oncology pipeline that addresses high-unmet-need tumors. At the same time, we believe the European Patent Office's recent rulings upholding two of our patents in amended form confirm the strength of our mRNA intellectual property estate. Backed by €438 million in cash, we are well positioned to unlock multiple pipeline catalysts later this year and continue to expand and execute on our next generation mRNA portfolio.'
Selected Business Updates
Oncology
CureVac is strengthening its oncology pipeline following two complementary approaches: off-the-shelf precision immunotherapies targeting tumor antigens shared across different patient populations and/or tumor types as well as fully personalized precision immunotherapies based on a patient's individual tumor genomic profile.
Prophylactic Vaccines
Protection of Intellectual Property Rights
Financial Update for the First Quarter of 2025
Cash Position
Cash and cash equivalents amounted to €438.3 million at the end of March 2025, decreasing from €481.7 million at the end of December 2024. In the first three months of 2025, cash used in operations was mainly allocated to ongoing research and development (R&D) activities to advance candidates in oncology precision immunotherapies and prophylactic vaccines and to further develop CureVac's mRNA technology. As a result of the strategic restructuring initiated in July 2024, the cash outflow for the first quarter of 2025 decreased compared to the first quarter of 2024. CureVac completed the intended workforce reduction as part of the strategic restructuring resulting in decreased personnel expenses, while implementing further cost reductions and increasing cost discipline through the organization. The company reaffirms its expected cash runway into 2028.
Revenues
Revenues amounted to €0.9 million for the first quarter of 2025, representing a decrease of €11.5 million from €12.4 million for the same period in 2024.
The year-on-year decrease was primarily driven by lower revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licence Agreement as well as lower sales to CRISPR Therapeutics.
For the three months ending March 31, 2025, total revenues of €0.3 million and €0.6 million were recognized with GSK and CRISPR Therapeutics, respectively, compared to €8.9 million and €3.5 million in the prior year period.
Operating Result
Operating loss amounted to €54.7 million for the first quarter of 2025, representing a decrease of €18.6 million from €73.3 million for the same period in 2024.
The decrease year-over-year is primary attributable to the implemented cost reductions initiated with the strategic restructuring in July 2024:
Financial Result (Finance Income and Expenses)
Net financial result for the first quarter of 2025 amounted to €3.0 million, representing a decrease of €0.4 million from €3.4 million for the same period in 2024.
Pre-Tax Loss
Pre-tax loss was €51.7 million for the first quarter of 2025, compared to €69.9 million in the same period of 2024.
About CureVac
CureVac (Nasdaq:CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized precision immunotherapy candidates to treat cancer. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.
CureVac Media and Investor Relations Contact
CureVac, Tübingen, Germany
T: +49 7071 9883-0
[email protected]
Forward-Looking Statements of CureVac
This press release contains statements that constitute 'forward looking statements' as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the 'company') regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway expectations, timing of various milestones, the impact of restructuring, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as 'anticipate,' 'intend,' 'believe,' 'estimate,' 'plan,' 'seek,' 'project,' 'expect,' 'may,' 'will,' 'would,' 'could,' 'potential,' 'intend,' or 'should,' the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, ability to implement our pipeline strategy, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, ability to implement, maintain and improve effective internal controls, reliance on key personnel, reliance on intellectual property protection and the company's and the company's collaborators' ability to obtain, maintain, defend and enforce such intellectual property, scope of intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes and other important factors discussed under the caption 'Risk Factors' in the company's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 11, 2025, as such factors may be updated form time to time in its other filings with the SEC. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's reports and documents filed with the SEC. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
Cash and Condensed Consolidated Profit and Loss Data
SOURCE: CureVac
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Washington Post
an hour ago
- Washington Post
Company involved in Coldplay KissCam drama hires Gwyneth Paltrow as spokesperson
BOSTON — Astronomer — the company whose CEO resigned after being caught on a KissCam at a Coldplay rock concert embracing a woman who was not his wife — is trying to move on from the drama with someone who knows the band pretty well. Actress Gwyneth Paltrow, who was married to Coldplay's frontman Chris Martin for 13 years, announced Friday on X that she has been hired by Astronomer as a spokesperson. Astronomer, a tech company based in New York, found itself in an uncomfortable spotlight when two of its executives were caught on camera in an intimate embrace at a Coldplay concert — a moment that was then flashed on a giant screen in the stadium. CEO Andy Byron and human resource executive Kristin Cabot were caught by surprise when Martin asked the cameras to scan the crowd during a concert earlier this month. 'Either they're having an affair or they're just very shy,' Martin joked when the couple appeared on screen and quickly tried to hide their faces. In a short video, the 'Shakespeare in Love' and 'Ironman' star said she had been hired as a 'very temporary' spokesperson for Astronomer. 'Astronomer has gotten a lot of questions over the last few days and they wanted me to answer the most common ones,' Paltrow said, smiling and deftly avoiding mention of the KissCam fuss. 'We've been thrilled that so many people have a newfound interest in data workflow automation,' she said. 'We will now be returning to what we do best — delivering game-changing results for our customers.' When footage from the KissCam first spread online, it wasn't immediately clear who the couple were. Soon after the company identified the pair, and Byron resigned followed by Cabot. The video clip resulted in a steady stream of memes, parody videos and screenshots of the pair's shocked faces filling social media feeds. Online streams of Coldplay's songs jumped 20% in the days after the video went viral, according to Luminate, an industry data and analytics company.
Associated Press
an hour ago
- Associated Press
Company involved in Coldplay KissCam drama hires Gwyneth Paltrow as spokesperson
BOSTON (AP) — Astronomer — the company whose CEO resigned after being caught on a KissCam at a Coldplay rock concert embracing a woman who was not his wife — is trying to move on from the drama with someone who knows the band pretty well. Actress Gwyneth Paltrow, who was married to Coldplay's frontman Chris Martin for 13 years, announced Friday on X that she has been hired by Astronomer as a spokesperson. Astronomer, a tech company based in New York, found itself in an uncomfortable spotlight when two of its executives were caught on camera in an intimate embrace at a Coldplay concert — a moment that was then flashed on a giant screen in the stadium. CEO Andy Byron and human resource executive Kristin Cabot were caught by surprise when Martin asked the cameras to scan the crowd during a concert earlier this month. 'Either they're having an affair or they're just very shy,' Martin joked when the couple appeared on screen and quickly tried to hide their faces. In a short video, the 'Shakespeare in Love' and 'Ironman' star said she had been hired as a 'very temporary' spokesperson for Astronomer. 'Astronomer has gotten a lot of questions over the last few days and they wanted me to answer the most common ones,' Paltrow said, smiling and deftly avoiding mention of the KissCam fuss. 'We've been thrilled that so many people have a newfound interest in data workflow automation,' she said. 'We will now be returning to what we do best — delivering game-changing results for our customers.' When footage from the KissCam first spread online, it wasn't immediately clear who the couple were. Soon after the company identified the pair, and Byron resigned followed by Cabot. The video clip resulted in a steady stream of memes, parody videos and screenshots of the pair's shocked faces filling social media feeds. Online streams of Coldplay's songs jumped 20% in the days after the video went viral, according to Luminate, an industry data and analytics company.
